These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29104172)

  • 1. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhône-Alpes region, France, January to August 2014: implications for antiviral treatment.
    Ramière C; Tremeaux P; Caporossi A; Trabaud MA; Lebossé F; Bailly F; Thélu MA; Nana J; Leroy V; Morand P; André P; Larrat S
    Euro Surveill; 2014 Oct; 19(43):. PubMed ID: 25375898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis C virus genotype 4: epidemiology and treatment].
    Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
    Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
    [No Abstract]   [Full Text] [Related]  

  • 4. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.
    Kurbanov F; Tanaka Y; Chub E; Maruyama I; Azlarova A; Kamitsukasa H; Ohno T; Bonetto S; Moreau I; Fanning LJ; Legrand-Abravanel F; Izopet J; Naoumov N; Shimada T; Netesov S; Mizokami M
    J Infect Dis; 2008 Nov; 198(10):1448-56. PubMed ID: 18928375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus genotype 4: Genotype 1's little brother.
    Llaneras J; Riveiro-Barciela M; Buti M; Esteban R
    J Viral Hepat; 2017 Jan; 24(1):4-12. PubMed ID: 27905173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 8. HCV genotype 5: epidemiology and spread of an uncommon genotype.
    Verbeeck J; Peigue-Lafeuille H; Ross RS; Abergel A; Nevens F; Van der Merwe S; Van Ranst M; Henquell C
    J Clin Virol; 2008 Feb; 41(2):170-1. PubMed ID: 18069057
    [No Abstract]   [Full Text] [Related]  

  • 9. Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.
    Trippoli S; Fadda V; Maratea D; Messori A
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):983-4. PubMed ID: 26114910
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C virus infection in end stage renal disease and after kidney transplant.
    Rodriguez-Castro KI; Morisco F; Rigotti P; Rugge M; Burra P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):340-2. PubMed ID: 25267966
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of hepatitis C virus genotypes.
    Mondelli MU; Silini E
    J Hepatol; 1999; 31 Suppl 1():65-70. PubMed ID: 10622563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus infection and genetic susceptibility to therapy.
    Sibbing B; Nattermann J
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):397-406. PubMed ID: 22187706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus.
    Samuel D
    J Hepatol; 2010 Jan; 52(1):3-4. PubMed ID: 19923033
    [No Abstract]   [Full Text] [Related]  

  • 16. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutics: new drugs hit the target.
    Schlütter J
    Nature; 2011 Jun; 474(7350):S5-7. PubMed ID: 21666733
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 19. Infection with hepatitis C virus genotype 3--experience of a tertiary health care centre in south India.
    David J; Rajasekar A; Daniel HD; Ngui SL; Ramakrishna B; Zachariah UG; Eapen CE; Abraham P
    Indian J Med Microbiol; 2010; 28(2):155-7. PubMed ID: 20404464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.